Perceptive Advisors

Founded 1999


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 154
Average round size
The average size of a deal this fund participated in
Portfolio companies 146
Rounds per year 7.00
Lead investments 43
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 82
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical

The venture was found in North America in United States. The main department of described VC is located in the New York.

We also calculated 3 valuable employees in our database.

The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2019. This Perceptive Advisors works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The typical startup value when the investment from Perceptive Advisors is 100-500 millions dollars. The common things for fund are deals in the range of 50 - 100 millions dollars. The increased amount of exits for fund were in 2018.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, BridgeBio, Alector. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Genetics, Biopharma.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Perceptive Advisors, startups are often financed by Third Rock Ventures, F-Prime Capital, Morgenthaler Ventures. The meaningful sponsors for the fund in investment in the same round are ArrowMark Partners, RTW Investments LLC, Viking Global Investors. In the next rounds fund is usually obtained by OrbiMed, Pontifax, Warburg Pincus.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Perceptive Advisors:
Typical Co-investors
Perceptive Advisors is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Perceptive Advisors:

Funds with similar focus

Funds from United States, New York
Funds with similar focus located in United States, New York:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation


Health Care
Life Science
$82M07 Sep 2021 United States, Boston

Genome Medical

Health Care
Life Science
$60M30 Aug 2021 United States, South San Francisco

Bridge to Life Ltd.

$56M19 Aug 2021 United States, Northbrook

Zentera Therapeutics

$75M04 Aug 2021 China, Shanghai


Artificial Intelligence
Health Care
Health Diagnostics
Machine Learning
Predictive Analytics
$350M23 Jul 2021 United States, Stamford

Point Biopharma

$165M01 Jul 2021 United States, Indianapolis

PROCEPT BioRobotics

Health Care
Medical Device
$85M30 Jun 2021 United States, Redwood City

Nautilus Biotechnology

Life Science
$200M10 Jun 2021 United States, " United States"}

NiKang Therapeutics

Health Care
$200M26 May 2021 United States, Wilmington
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures. – The pro... Read more
Emulate Closes $82 Million Series E Financing to Scale Amid Rapid Growth in Organ-on-a-Chip Market
– Emulate, Inc. announced the close of an $82m Series E financing round. – The round was led by Northpond Ventures with additional participation from Perceptive Advisors. – With this investment, Emulate has raised nearly $225m to date. – Emulate develops and manufactures next-generation in vitro models that enable researchers to replicate and study human biology and disease, helping them understand and predict drug response with greater precision and detail than possible with conventional cell culture or a... Read more


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Perceptive Advisors?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: